Literature DB >> 25365984

How to train your oncolytic virus: the immunological sequel.

Richard G Vile1.   

Abstract

Mesh:

Substances:

Year:  2014        PMID: 25365984      PMCID: PMC4429744          DOI: 10.1038/mt.2014.188

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  25 in total

1.  CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.

Authors:  Christine E Engeland; Christian Grossardt; Rūta Veinalde; Sascha Bossow; Diana Lutz; Johanna K Kaufmann; Ivan Shevchenko; Viktor Umansky; Dirk M Nettelbeck; Wilko Weichert; Dirk Jäger; Christof von Kalle; Guy Ungerechts
Journal:  Mol Ther       Date:  2014-08-26       Impact factor: 11.454

2.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

Review 3.  Live viruses to treat cancer.

Authors:  Oliver Donnelly; Kevin Harrington; Alan Melcher; Hardev Pandha
Journal:  J R Soc Med       Date:  2013-07-03       Impact factor: 5.344

Review 4.  Recent clinical experience with oncolytic viruses.

Authors:  O G Donnelly; F Errington-Mais; R Prestwich; K Harrington; H Pandha; R Vile; A A Melcher
Journal:  Curr Pharm Biotechnol       Date:  2012-07       Impact factor: 2.837

5.  Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.

Authors:  Neil N Senzer; Howard L Kaufman; Thomas Amatruda; Mike Nemunaitis; Tony Reid; Gregory Daniels; Rene Gonzalez; John Glaspy; Eric Whitman; Kevin Harrington; Howard Goldsweig; Tracey Marshall; Colin Love; Robert Coffin; John J Nemunaitis
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

Review 6.  Going viral with cancer immunotherapy.

Authors:  Brian D Lichty; Caroline J Breitbach; David F Stojdl; John C Bell
Journal:  Nat Rev Cancer       Date:  2014-07-03       Impact factor: 60.716

Review 7.  The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.

Authors:  Robin J Prestwich; Fiona Errington; Rosa M Diaz; Hardev S Pandha; Kevin J Harrington; Alan A Melcher; Richard G Vile
Journal:  Hum Gene Ther       Date:  2009-10       Impact factor: 5.695

8.  Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.

Authors:  Jedd D Wolchok; James P Allison; Dmitriy Zamarin; Rikke B Holmgaard; Sumit K Subudhi; Joon Seok Park; Mena Mansour; Peter Palese; Taha Merghoub
Journal:  Sci Transl Med       Date:  2014-03-05       Impact factor: 17.956

Review 9.  CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.

Authors:  Patrick A Ott; F Stephen Hodi; Caroline Robert
Journal:  Clin Cancer Res       Date:  2013-10-01       Impact factor: 12.531

Review 10.  Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity.

Authors:  Zong Sheng Guo; Zuqiang Liu; David L Bartlett
Journal:  Front Oncol       Date:  2014-04-10       Impact factor: 6.244

View more
  5 in total

1.  Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment.

Authors:  Lukasz Kuryk; Lotta Vassilev; Tuuli Ranki; Akseli Hemminki; Aila Karioja-Kallio; Onerva Levälampi; Antti Vuolanto; Vincenzo Cerullo; Sari Pesonen
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

Review 2.  Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies.

Authors:  Amelia Sadie Aitken; Dominic Guy Roy; Marie-Claude Bourgeois-Daigneault
Journal:  Biomedicines       Date:  2017-01-04

3.  Oncolytic vesicular stomatitis virus expressing interferon-γ has enhanced therapeutic activity.

Authors:  Marie-Claude Bourgeois-Daigneault; Dominic Guy Roy; Theresa Falls; Kwame Twumasi-Boateng; Lauren Elizabeth St-Germain; Monique Marguerie; Vanessa Garcia; Mohammed Selman; Victoria Ann Jennings; Jessica Pettigrew; Sally Amos; Jean-Simon Diallo; Brad Nelson; John Cameron Bell
Journal:  Mol Ther Oncolytics       Date:  2016-02-17       Impact factor: 7.200

Review 4.  Assessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly"?

Authors:  Benjamin Ruf; Ulrich M Lauer
Journal:  Mol Ther Oncolytics       Date:  2015-11-04       Impact factor: 7.200

Review 5.  How Computational Chemistry and Drug Delivery Techniques Can Support the Development of New Anticancer Drugs.

Authors:  Mariangela Garofalo; Giovanni Grazioso; Andrea Cavalli; Jacopo Sgrignani
Journal:  Molecules       Date:  2020-04-10       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.